FIELD: pharmaceuticals.
SUBSTANCE: group of inventions refers to an antibody or its antigen-binding fragment which specifically binds CD127 and use of said antibody or its antigen-binding fragment. Antibody or its antigen-binding fragment contains a VH-chain containing the following amino acid sequences VHCDR1 SEQ ID No: 10, VHCDR2 SEQ ID No: 12, VHCDR3 SEQ ID No: 14 or SEQ ID No: 48; and a VL-chain comprising the following amino acid sequences VLCDR1 SEQ ID No: 16 or SEQ ID No: 50; VLCDR2 SEQ ID No: 18 or SEQ ID No: 52; VLCDR3 SEQ ID No: 20. Also disclosed are a macromolecule which is a conjugate and containing said antibody or its antigen-binding fragment; nucleic acid molecule, coding antibody or its antigen-binding fragment. Disclosed also is a pharmaceutical composition comprising said antibody or antigen-binding fragment thereof, or said macromolecule, or said nucleic acid molecule. Said antibody or its antigen-binding fragment, macromolecule, nucleic acid molecule, pharmaceutical composition can be used for treating condition, which can be improved or prevented by IL7-induced signaling IL7-R antagonisation. What is also presented is a method of treating, a method for producing the antibody and a method for selecting the antibody.
EFFECT: disclosed antibody or its antigen-binding fragment is highly effective.
35 cl, 12 tbl, 21 ex, 28 dwg
Title | Year | Author | Number |
---|---|---|---|
ANTIBODIES AND POLYPEPTIDES AGAINST CD127 | 2017 |
|
RU2769352C2 |
IL-12 HETERODIMERIC FC FUSION PROTEINS | 2019 |
|
RU2819097C2 |
COMPOSITION FOR PREVENTION OR TREATMENT OF IL-8-RELATED DISEASES | 2017 |
|
RU2766112C2 |
COMPOSITION FOR CULTURING REGULATORY T-CELLS AND ITS APPLICATION | 2020 |
|
RU2807802C1 |
LIGAND-BINDING MOLECULE WITH REGULATED LIGAND-BINDING ACTIVITY | 2017 |
|
RU2803067C2 |
POLYPEPTIDE COMPRISING ANTIGEN-BINDING DOMAIN AND TRANSPORT SEGMENT | 2018 |
|
RU2815452C2 |
MONOCLONAL ANTIBODIES TO INTERLEUKIN-31 FOR VETERINARY USE | 2019 |
|
RU2795411C2 |
FULLY HUMAN MESOTHELIN ANTIBODIES AND IMMUNE EFFECTOR CELLS TARGETING MESOTHELIN | 2016 |
|
RU2748281C2 |
ANTI-HLA-A2 ANTIBODIES AND THEIR APPLICATION METHODS | 2018 |
|
RU2782276C2 |
CD131-BINDING PROTEINS AND THEIR APPLICATIONS | 2016 |
|
RU2773927C2 |
Authors
Dates
2020-10-12—Published
2015-06-10—Filed